These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16636494)

  • 1. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Aizawa Y; Komura S; Hosaka Y; Tanabe Y; Furushima H; Aizawa Y
    Circ J; 2006 May; 70(5):583-7. PubMed ID: 16636494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Komura S; Hosaka Y; Tanabe Y; Furushima H; Fujita S; Kato K; Aizawa Y
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):285-90. PubMed ID: 15826260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
    Hoffmann E; Mattke S; Haberl R; Steinbeck G
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia.
    Igawa M; Aonuma K; Okamoto Y; Hiroe M; Hiraoka M; Isobe M
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):735-42. PubMed ID: 12409982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
    Antz M; Cappato R; Kuck KH
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias.
    Otuki S; Hasegawa K; Watanabe H; Katsuumi G; Yagihara N; Iijima K; Sato A; Izumi D; Furushima H; Chinushi M; Aizawa Y; Minamino T
    J Electrocardiol; 2017; 50(3):277-281. PubMed ID: 28238302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
    Steinbeck G; Bach P; Haberl R
    J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.
    Kehoe RF; MacNeil DJ; Zheutlin TA; Ezri MD; Nazari J; Spangenberg RB; Dunnington C; Lueken M
    Am J Cardiol; 1993 Aug; 72(4):56A-66A. PubMed ID: 8346728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
    Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M
    Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
    Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifekalant hydrochloride suppresses severe electrical storm in patients with malignant ventricular tachyarrhythmias.
    Washizuka T; Chinushi M; Watanabe H; Hosaka Y; Komura S; Sugiura H; Hirono T; Furushima H; Tanabe Y; Aizawa Y
    Circ J; 2005 Dec; 69(12):1508-13. PubMed ID: 16308500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
    Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
    Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nifekalant hydrochloride terminated electrical storms after coronary surgery.
    Kurisu K; Hisahara M; Onitsuka H; Sekiya M; Ikeuchi M; Kozai T; Urabe Y
    Ann Thorac Surg; 2010 May; 89(5):1637-9. PubMed ID: 20417798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders.
    Naitoh N; Yamaura M; Tagawa M; Aizawa Y
    Jpn Heart J; 1998 Sep; 39(5):619-30. PubMed ID: 9925993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation.
    Katoh T; Mitamura H; Matsuda N; Takano T; Ogawa S; Kasanuki H
    Circ J; 2005 Oct; 69(10):1237-43. PubMed ID: 16195624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
    Lee SD; Newman D; Ham M; Dorian P
    J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.